Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.45 |
| ▸ | ENPP3 | O14638 | 4/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 3/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | IGFBP5 | P24593 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17443020 | 0.91 | TP53 (0.44) | TP53ENPP3ENPP1NPC1NR2F2 | |
| SCHEMBL17440066 | 0.89 | TP53 (0.47) | TP53ENPP3ENPP1NPC1NR2F2 | |
| SCHEMBL17440138 | 0.87 | CHRM1 (0.44) | TP53ENPP3ENPP1MRGPRX4POLB | |
| SCHEMBL17440146 | 0.81 | CHRM1 (0.51) | CHRM1 | |
| SCHEMBL17440117 | 0.79 | CHRM1 (0.65) | CHRM1 | |
| SCHEMBL17440096 | 0.79 | CHRM1 (0.65) | CHRM1 | |
| SCHEMBL17450461 | 0.78 | CHRM1 (0.45) | TP53ENPP3ENPP1POLBTHRB | |
| SCHEMBL20031037 | 0.74 | DHODH (0.40) | TP53ENPP3ENPP1MRGPRX4POLB | |
| SCHEMBL17450409 | 0.71 | KDM4E (0.36) | POLBTDP1IGFBP5KDM4EL3MBTL1 | |
| SCHEMBL17440130 | 0.70 | CHRM1 (0.61) | NPC1RAB9AKMOTDP1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016009297-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016009297-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM4 | TP53 2420/4885ENPP3 1766/4885ENPP1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.